Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > de G

<< Previous

Bullboard Posts

Next >>

Comment by jh1970on Dec 13, 2023 4:17pm

167 Views

Post# 35783066

RE:RE:RE:de G

Filed 2023-12-13 15:03 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Heineman, Thomas 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 56 - Grant of rights	+62,100 vol	86,000
Filed 2023-12-13 15:02 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Heineman, Thomas 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$442,547 +231,700 vol $1.91 each	745,600
Filed 2023-12-13 15:00 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Hagerman, Allison 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 56 - Grant of rights	+19,500 vol	25,400
Filed 2023-12-13 14:59 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Hagerman, Allison 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$139,048 +72,800 vol $1.91 each	602,183
Filed 2023-12-13 14:57 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Look, Kirk 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 56 - Grant of rights	+62,100 vol	90,300
Filed 2023-12-13 14:57 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Look, Kirk 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$442,547 +231,700 vol $1.91 each	1,098,962
Filed 2023-12-13 14:54 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Coffey, Matthew 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Rights Restricted Share Units 56 - Grant of rights	+93,800 vol	174,500
Filed 2023-12-13 14:52 Tx date 2023-12-08	$ONC Oncolytics Biotech Inc.	Coffey, Matthew 4 - Director of Issuer, 5 - Senior Officer of Issuer Direct Ownership	Options 50 - Grant of options	$668,500 +350,000 vol $1.91 each	1,855,631
Filed 2023-12-12 09:57 Tx date 2023-12-11	$ONC Oncolytics Biotech Inc.	Hagerman, Allison 5 - Senior Officer of Issuer Direct Ownership	Options 52 - Expiration of options	-2,105 vol
Filed 2023-12-12 09:54 Tx date 2023-12-11	$ONC Oncolytics Biotech Inc.	Pisano, Wayne 4 - Director of Issuer Direct Ownership	Options 52 - Expiration of options	-3,157 vol	112,500